Who
Christopher Ogden
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, CytomX Therapeutics.
In numbers
- Trades disclosed
- 37
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $309K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 10 Aug 2022
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,9531,624 at $3.05 | filing |
| 15 Jun 2026filed 17 Jun 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,9531,624 at $3.05 | filing |
| 17 Mar 2026filed 19 Mar 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $124K19,323 at $6.42 | filing |
| 17 Mar 2026filed 19 Mar 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $124K19,323 at $6.42 | filing |
| 2 Feb 2026filed 4 Feb 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —325,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —325,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 26 Sep 2025filed 30 Sep 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,250 at $0.00 | filing |
| 26 Sep 2025filed 30 Sep 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,150 at $0.00 | filing |
| 16 Jun 2025filed 17 Jun 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $29K10,614 at $2.69 | filing |
| 13 Jun 2025filed 17 Jun 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —37,500 at $0.00 | filing |
| 13 Jun 2025filed 17 Jun 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,8411,641 at $2.95 | filing |
| 13 Jun 2025filed 17 Jun 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code M | —37,500 at $0.00 | filing |
| 18 Mar 2025filed 20 Mar 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,1318,551 at $0.60 | filing |
| 4 Feb 2025filed 6 Feb 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 4 Feb 2025filed 6 Feb 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 4 Feb 2025filed 6 Feb 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 4 Feb 2025filed 6 Feb 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —57,500 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,875 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.